top of page
VUZE_at_a_Glance_02_10_00_2400.jpg
Vuze_Logo@2x@2x.png

About Us

VUZE Medical was incorporated in 2017 in Israel and is financed privately.  Milestones so far include high accuracy and speed on an anatomical model (2018) and in cadaveric surgeries (2019-2020), a first US Patent (2020, with seven more since), first European and Asian patents (2021), FDA 510(k) submission (2021), successful first-in-human surgery (late 2021), FDA 510(k) clearance for minimally-invasive thoracolumbar fixation and augmentation  (2022), the completion of a highly-successful twenty-patient clinical trial (early 2023), cadaveric proofs of concept for pain therapy, sacral  fusions and open surgery (mid 2023) and a second FDA 510(k) clearance including co-operability with a very broad range of 3D and 2D imaging sources from all major vendors (mid 2024).

Team

Extensive Experience and a Strong Track Record

A veteran team brings strong domain expertise in adding computer guidance to common manual interventions. Our two prior endeavors have each become a Standard of Care in its respective field: superDimension (now Medtronic) in bronchoscopies with 1,000 installations worldwide, and SyncVision (now Philips) in coronary catheterizations with 4,000 installations worldwide.


Sigi Elazar  UI & UX
Adi Akavian  testing & support
Neta Stern  software
Koby Zakaeim  application engineering
Asaf Omer  
QA & RA â€‹


Ran Cohen  CTO
Yoav Stein  ​software
Rivay Mor  algorithms
Sasha Steinberg  algorithms
David Tolkowsky  CEO

right to left:

Team

13 Zarhin St., Entrance A, Floor 7
Ra’anana 4366241, Israel

Copyright © 2024 VUZE Medical Ltd. All rights reserved. Proprietary. Patents granted. Patents pending. The VUZE system, VUZE software and Dynamic Online Image Registration (DOLIR) are trademarks of VUZE Medical.

bottom of page